Jiang Liu

Ueruemqi, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Correction: Clinical features, diagnostic difficulties and therapeutic enlightenment of adult-onset multisystem Langerhans cell histiocytosis complicated with panhypopituitarism and central diabetes insipidus: a case report and systematic literature review.

Correction: Clinical features, diagnostic difficulties and therapeutic enlightenment of adult-onset multisystem Langerhans cell histiocytosis complicated with panhypopituitarism and central diabetes insipidus: a case report and systematic literature review.

Journal: Frontiers in oncology

Published: July 13, 2026

Clinical features, diagnostic difficulties and therapeutic enlightenment of adult-onset multisystem Langerhans cell histiocytosis complicated with panhypopituitarism and central diabetes insipidus: a case report and systematic literature review.

Clinical features, diagnostic difficulties and therapeutic enlightenment of adult-onset multisystem Langerhans cell histiocytosis complicated with panhypopituitarism and central diabetes insipidus: a case report and systematic literature review.

Journal: Frontiers in oncology

Published: April 29, 2026

Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III Trial.

Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III Trial.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: June 26, 2025

Intravenous Patient-Controlled Analgesia Versus Oral Opioid to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase II Trial.

Intravenous Patient-Controlled Analgesia Versus Oral Opioid to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase II Trial.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 06, 2022

A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer.

A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer.

Journal: Therapeutic advances in medical oncology

Published: December 21, 2021

Clinical and Prognostic Significance of CD117 in Non-Small Cell Lung Cancer: A Systemic Meta-Analysis.

Clinical and Prognostic Significance of CD117 in Non-Small Cell Lung Cancer: A Systemic Meta-Analysis.

Journal: Pathobiology : journal of immunopathology, molecular and cellular biology

Published: November 05, 2020

EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib.

EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib.

Journal: Annals of translational medicine

Published: June 18, 2019

Choice of Capecitabine or S1 in Combination with Oxaliplatin based on Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase Expression Status in Patients with Advanced Gastric Cancer.

Choice of Capecitabine or S1 in Combination with Oxaliplatin based on Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase Expression Status in Patients with Advanced Gastric Cancer.

Journal: Journal of gastric cancer

Published: March 05, 2019

Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer.

Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer.

Journal: OncoTargets and therapy

Published: August 09, 2013

Showing 1-9 of 9

Last Updated: 09/26/2026